92 related articles for article (PubMed ID: 22192782)
21. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.
Sanli Y; Kuyumcu S; Ozkan ZG; Kilic L; Balik E; Turkmen C; Has D; Isik G; Asoglu O; Kapran Y; Adalet I
Ann Nucl Med; 2012 Aug; 26(7):551-8. PubMed ID: 22644560
[TBL] [Abstract][Full Text] [Related]
22. Positron emission tomography and colorectal cancer.
Arulampalam TH; Costa DC; Loizidou M; Visvikis D; Ell PJ; Taylor I
Br J Surg; 2001 Feb; 88(2):176-89. PubMed ID: 11167864
[TBL] [Abstract][Full Text] [Related]
23. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
24. The clinical application of positron emission tomography to colorectal cancer management.
Arulampalam TH; Costa DC; Bomanji JB; Ell PJ
Q J Nucl Med; 2001 Sep; 45(3):215-30. PubMed ID: 11788814
[TBL] [Abstract][Full Text] [Related]
25. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
Artiko V; Odalovic S; Sobic-Saranovic D; Petrovic M; Stojiljkovic M; Petrovic N; Kozarevic N; Grozdic-Milojevic I; Obradovic V
Hell J Nucl Med; 2015; 18(1):35-41. PubMed ID: 25840571
[TBL] [Abstract][Full Text] [Related]
26. Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography predicts extrahepatic metastatic potential of colorectal metastasis: a practical guide for yttrium-90 microsphere liver-directed therapy.
Wong CY; Gates VL; Tang B; Campbell J; Qing F; Lewandowski RJ; Thie J; Ho CL; Savin M; Salem R
Cancer Biother Radiopharm; 2010 Apr; 25(2):233-6. PubMed ID: 20423237
[TBL] [Abstract][Full Text] [Related]
27. Controversies in the management of colorectal liver metastases: role of PET and PET/CT.
Wiering B; Vogel WV; Ruers TJ; Oyen WJ
Dig Surg; 2008; 25(6):413-20. PubMed ID: 19212113
[TBL] [Abstract][Full Text] [Related]
28. A prognostic system applicable to patients with resectable liver metastasis from colorectal carcinoma staged by positron emission tomography with [18F]fluoro-2-deoxy-D-glucose: role of primary tumor variables.
Tan MC; Castaldo ET; Gao F; Chari RS; Linehan DC; Wright JK; Hawkins WG; Siegel BA; Delbeke D; Pinson CW; Strasberg SM
J Am Coll Surg; 2008 May; 206(5):857-68; discussion 868-9. PubMed ID: 18471711
[TBL] [Abstract][Full Text] [Related]
29. Serum carcinoembryonic antigen measurement, abdominal contrast-enhanced computed tomography, and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of colorectal cancer recurrence: a correlative study.
Ozkan E; Soydal C; Araz M; Aras G
Nucl Med Commun; 2012 Sep; 33(9):990-4. PubMed ID: 22842225
[TBL] [Abstract][Full Text] [Related]
30. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level.
Lee JH; Park SG; Jee KN; Park DG; Namgung H; Song IH
Nucl Med Commun; 2010 Jun; 31(6):576-82. PubMed ID: 20216474
[TBL] [Abstract][Full Text] [Related]
31. Comparison of diffusion-weighted MRI and 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for detecting primary colorectal cancer and regional lymph node metastases.
Ono K; Ochiai R; Yoshida T; Kitagawa M; Omagari J; Kobayashi H; Yamashita Y
J Magn Reson Imaging; 2009 Feb; 29(2):336-40. PubMed ID: 19161185
[TBL] [Abstract][Full Text] [Related]
32. [Combined FDG PET/CT imaging for restaging of colorectal cancer patients: impact of image fusion on staging accuracy].
Strunk H; Bucerius J; Jaeger U; Joe A; Flacke S; Reinhardt M; Hortling N; Palmedo H
Rofo; 2005 Sep; 177(9):1235-41. PubMed ID: 16123869
[TBL] [Abstract][Full Text] [Related]
33. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.
Lonneux M; Reffad AM; Detry R; Kartheuser A; Gigot JF; Pauwels S
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):915-21. PubMed ID: 12111132
[TBL] [Abstract][Full Text] [Related]
34. Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup.
Zervos EE; Badgwell BD; Burak WE; Arnold MW; Martin EW
Surgery; 2001 Oct; 130(4):636-43; discussion 643-4. PubMed ID: 11602894
[TBL] [Abstract][Full Text] [Related]
35. [The role of positron emission tomography (PET) in the detection of local recurrence and metastases of colorectal cancer].
Kanyári Z; Orosz L; Juhász B; Tanyi M; Németh E; Trón L; Damjanovich L; Lukács G; Kálvin B
Magy Seb; 2005 Jun; 58(3):179-83. PubMed ID: 16167472
[TBL] [Abstract][Full Text] [Related]
36. Clinical application of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in breast cancer.
Bernsdorf M; Graff J
Clin Physiol Funct Imaging; 2014 Nov; 34(6):426-33. PubMed ID: 24267489
[TBL] [Abstract][Full Text] [Related]
37. Utility of 18-fluorodeoxyglucose positron emission/computed tomography in the management of recurrent colorectal cancer.
Liong SY; Kochhar R; Renehan AG; Manoharan P
ANZ J Surg; 2012 Oct; 82(10):729-36. PubMed ID: 22989147
[TBL] [Abstract][Full Text] [Related]
38. Incremental value of CT in PET/CT of patients with colorectal carcinoma.
Kamel IR; Cohade C; Neyman E; Fishman EK; Wahl RL
Abdom Imaging; 2004; 29(6):663-8. PubMed ID: 15162236
[TBL] [Abstract][Full Text] [Related]
39. Baseline staging tests in primary breast cancer: a practice guideline.
Myers RE; Johnston M; Pritchard K; Levine M; Oliver T;
CMAJ; 2001 May; 164(10):1439-44. PubMed ID: 11387916
[TBL] [Abstract][Full Text] [Related]
40. Predictors of initial 18F-fluorodeoxyglucose-positron emission tomography indication among patients with colorectal cancer.
Zafar HM; Kramer S; Bonaccorsi D; Langlotz CP; Armstrong K
Nucl Med Commun; 2012 Jul; 33(7):739-46. PubMed ID: 22531828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
